Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug611 | Biological data Wiki | 0.39 |
| drug1004 | Clinical data Wiki | 0.32 |
| drug3559 | RUC-4 Compound Wiki | 0.28 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug166 | AVP 4 Wiki | 0.28 |
| drug167 | AVP I Wiki | 0.28 |
| drug4768 | Xpert Pro stent Wiki | 0.28 |
| drug3074 | Pacel BPC Wiki | 0.28 |
| drug60 | 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients) Wiki | 0.28 |
| drug3075 | Pacel FDPC Wiki | 0.28 |
| drug61 | 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ) Wiki | 0.28 |
| drug4319 | Telemedicine visit Wiki | 0.28 |
| drug35 | 18F-GP1 PET CT Wiki | 0.28 |
| drug197 | Absolute Pro LL stent Wiki | 0.28 |
| drug2463 | MI-CBT Wiki | 0.28 |
| drug2100 | Inactivated SARS CoV 2 vaccine (Vero cell). Wuhan Wiki | 0.28 |
| drug3376 | PressureWire X Wiki | 0.28 |
| drug4184 | Supera 7.5 OD stent Wiki | 0.28 |
| drug2488 | MULTI-LINK 8 SV stent Wiki | 0.28 |
| drug2487 | MULTI-LINK 8 LL stent Wiki | 0.28 |
| drug4764 | XIENCE PRIME BTK stent Wiki | 0.28 |
| drug2489 | MULTI-LINK 8 stent Wiki | 0.28 |
| drug3132 | Percutaneous Coronary Revascularization for STEMI Wiki | 0.28 |
| drug168 | AVP II Wiki | 0.28 |
| drug640 | Blood Transfusion Wiki | 0.28 |
| drug4872 | cardiac magnetic resonance Wiki | 0.28 |
| drug2099 | In-person postoperative visit Wiki | 0.28 |
| drug4857 | blood donation SMS Wiki | 0.16 |
| drug2827 | No intervention Wiki | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009203 | Myocardial Ischemia NIH | 0.77 |
| D000072657 | ST Elevation Myocardial Infarction NIH | 0.32 |
| D016757 | Death, Sudden, Cardiac NIH | 0.28 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D023903 | Coronary Restenosis NIH | 0.28 |
| D017180 | Tachycardia, Ventricular NIH | 0.28 |
| D004617 | Embolism NIH | 0.20 |
| D002546 | Ischemic Attack, Transient NIH | 0.20 |
| D013610 | Tachycardia NIH | 0.16 |
| D006331 | Heart Diseases NIH | 0.14 |
| D011655 | Pulmonary Embolism NIH | 0.14 |
| D016769 | Embolism and Thrombosis NIH | 0.14 |
| D003643 | Death, NIH | 0.14 |
| D014652 | Vascular Diseases NIH | 0.14 |
| D020521 | Stroke NIH | 0.13 |
| D003327 | Coronary Disease NIH | 0.10 |
| D013927 | Thrombosis NIH | 0.10 |
| D007511 | Ischemia NIH | 0.10 |
| D003324 | Coronary Artery Disease NIH | 0.09 |
| D009205 | Myocarditis NIH | 0.09 |
| D058186 | Acute Kidney Injury NIH | 0.05 |
| D004194 | Disease NIH | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001658 | Myocardial infarction HPO | 0.77 |
| HP:0004756 | Ventricular tachycardia HPO | 0.28 |
| HP:0001645 | Sudden cardiac death HPO | 0.28 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002326 | Transient ischemic attack HPO | 0.20 |
| HP:0001649 | Tachycardia HPO | 0.16 |
| HP:0002204 | Pulmonary embolism HPO | 0.14 |
| HP:0001297 | Stroke HPO | 0.13 |
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.09 |
| HP:0012819 | Myocarditis HPO | 0.09 |
| HP:0001907 | Thromboembolism HPO | 0.06 |
| HP:0001919 | Acute kidney injury HPO | 0.05 |
Navigate: Correlations HPO
There are 13 clinical trials
The goal of the proposed study is to determine whether a liberal transfusion strategy (transfusion trigger at Hb < 10 gm/dl) in Veterans at high cardiac risk who undergo major open vascular and general surgery operations is associated with decreased risk of adverse postoperative outcomes compared to a restrictive transfusion strategy (transfusion trigger at Hb < 7 gm/dl).
Description: MI will be defined using the Third Universal Definition of Myocardial Infarction. Acute renal failure will be defined as Acute Kidney Injury stage III according to RIFLE criteria. Baseline creatinine will be considered the creatinine upon admission prior to the index operation. The above urine output criteria will be only used for patients who are in the ICU and have precise monitoring of their urinary output. For patients on the surgical floor only serum creatinine changes will be used for assessment of this endpoint. Coronary revascularization will be defined as a coronary artery bypass graft, or percutaneous coronary intervention (either angioplasty or stenting). Stroke will be defined as new unilateral neurological deficit that lasts for more than 24 hours, and is confirmed by a brain imaging modality (computed tomography or magnetic resonance imaging study) demonstrating new brain infarct.
Measure: A composite endpoint of all-cause post-randomization mortality, myocardial infarction (MI), coronary revascularization, acute renal failure, or post-randomization ischemic stroke up to 90 days after randomization. Time: 90 days after randomizationDescription: Wound infection will be defined according to the Centers for Disease Control and Prevention (CDC) guidelines as a) positive wound culture, or b) drainage of pus from a wound, or c) suspicion of wound infection that was drained operatively. Pneumonia will be defined according to the CDC definition as chest radiograph with new or progressive infiltrate, consolidation, cavitation, or pleural effusion and any of the following: new onset of purulent sputum or change in character of sputum, or organism isolated from blood culture, trans-tracheal aspirate, bronchial brushings, or biopsy. Sepsis will be defined as a combination of two of the following systemic inflammatory response syndrome (SIRS) criteria, plus suspected or present source of infection. SIRS criteria will include the following: temperature greater than 38C, heart rate greater than 90 beats/min, WBC > 12,000 or < 4,000, or > 10% bands.
Measure: A composite endpoint of postoperative infectious complications at 90 days post-randomization: Infectious complications will include wound infections, pneumonia, and sepsis. Time: 90 days after randomizationDescription: The diagnosis of cardiac arrhythmias will be based on EKG findings. Only arrhythmias that result in initiation of new treatment regimen (to include medications, implantable devices, or surgical intervention) during hospitalization will be recorded. CHF will require at least one of the following symptoms or signs new or worsening: dyspnea at rest, orthopnea, or paroxysmal nocturnal dyspnea and radiological evidence of heart failure or worsening heart failure and increase/initiation of established treatment. Cardiac arrest will be defined as the cessation of cardiac pump function activity that results in loss of consciousness and absence of circulating blood flow as evidenced by absent carotid pulse. Only episodes of cardiac arrest that are reversed will be collected under this endpoint. If they are not reversed the event will be categorized as death.
Measure: A composite endpoint of cardiac complications (other than MI) at 90 days post-randomization: Cardiac complications will include new cardiac arrhythmias that necessitate new treatment, new or worsening congestive heart failure (CHF), and cardiac arrest no Time: 90 days after randomizationDescription: The investigators will determine vital status by telephoning participants after hospital discharge, by searching the electronic medical record and the National Death Index.
Measure: All-cause mortality at 1 year after randomization. Time: 12 months after randomizationDescription: MI, coronary revascularization, acute renal failure, or postoperative ischemic stroke.
Measure: A composite endpoint of all-cause mortality, Time: 30 days after randomizationDescription: Length of hospital stay
Measure: Length of hospital stay. Time: At hospital discharge, up to 1 yearDescription: All cause postoperative mortality, Postoperative MI, Postoperative coronary revascularization, Postoperative stroke,Postoperative acute renal failure
Measure: The investigators will examine individual rates of the outcomes that consist of individual components of the primary endpoint. Time: 90 days after randomizationTo date, the investigators have successfully employed a radiotracer (18F-sodium fluoride) as a marker of necrotic inflammation in human atherosclerosis. The investigators aim to further the mechanistic understanding of atherothrombosis by studying the activation of glycoprotein IIb/IIIa receptors in cardiovascular thrombus using the novel platelet radiotracer (18F-GP1). Binding of 18F-GP1 to activated platelets in venous and arterial thrombi has already been demonstrated in pre-clinical studies and a phase 1 trial in man. If successful, this study would define the role of the glycoprotein IIb/IIIa receptor within in vivo thrombosis across a range of cardiovascular diseases.
Description: Expression of the glycoprotein IIb/IIIa receptor (assessed by SUV) within thrombus in the arterial and venous circulation.
Measure: Ratio of 18F-GP1 standardised uptake values (SUV's) in thrombus compared with the SUVs recorded in the blood pool. Time: 6 months from end of recruitmentDescription: Expression of the glycoprotein IIb/IIIa receptor (assessed by SUV) within thrombus in the arterial and venous circulation in all 5 disease states
Measure: Ratio of 18F-GP1 standardised uptake values (SUV's) in thrombus formed in each of the 5 disease states. Time: 6 months from end of recruitmentRUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration. This study is designed to extend the findings in CEL-01 to patients with ST-elevation myocardial Infarction (STEMI) presenting to the cardiac catheterization laboratory with planned coronary angioplasty.
Description: Inhibition of Platelet Aggregation
Measure: Platelet Inhibition Time: BaselineDescription: Inhibition of Platelet aggregation
Measure: Platelet Inhibition Time: 15 minutesDescription: Inhibition of Platelet aggregation
Measure: Platelet inhibition Time: 45 minutesDescription: Inhibition of Platelet aggregation
Measure: Platelet inhibition Time: 60 minutesDescription: Inhibition of Platelet aggregation
Measure: Platelet inhibition Time: 90 minutesDescription: Inhibition of Platelet aggregation
Measure: Platelet inhibition Time: 120 minutesDescription: Inhibition of Platelet aggregation
Measure: Platelet inhibition Time: 180 minutesDescription: concentration in blood (ng/mL)
Measure: RUC-4 Concentration Time: BaselineDescription: concentration in blood (ng/mL)
Measure: RUC-4 Concentration Time: 15 minutesDescription: concentration in blood (ng/mL)
Measure: RUC-4 Concentration Time: 45 minutesDescription: concentration in blood (ng/mL)
Measure: RUC-4 Concentration Time: 90 minutesDescription: concentration in blood (ng/mL)
Measure: RUC-4 Concentration Time: 120 minutesDescription: concentration in blood (ng/mL)
Measure: RUC-4 Concentration Time: 180 minutesDescription: Bleeding events, Injection site reactions,vital signs, ECG, laboratory results
Measure: Safety and Tolerability Time: BaselineDescription: Bleeding events, Injection site reactions,vital signs, ECG, laboratory results
Measure: Safety and Tolerability Time: Hospital dischargeDescription: concentration in blood (ng/mL)
Measure: RUC-4 Concentration Time: 240 minutesDescription: Inhibition of platelet aggregation
Measure: Platelet aggregation Time: 240 minutesIn late December 2019, an emerging disease due to a novel coronavirus (named SARS-CoV-2) rapidly spread in China and outside. France is currently facing the COVID-19 wave with more than 131 863 confirmed cases and almost 25 201 deaths. Systems of care have been reorganized in an effort to preserve hospital bed capacity, resources, and avoid exposure of patients to the hospital environment where COVID-19 may be more prevalent. Therefore, elective procedures of catheterization and programmed hospitalizations have been delayed. However, a significant proportion of procedures within the catheterization laboratory such as ST-elevation myocardial infarction (STEMI), non ST elevation myocardial infarction or unstable angina are mandatory and cannot be postponed. Surprisingly, invasive cardiologist noticed a drop in STEMI volume without reliable data to confirm this impression. Furthermore, a recent single center report in Hong Kong pointed out longer delays of taking care when compared to patients with STEMI treated with percutaneous intervention the previous year. These data are at major concern because delay in seeking care or not seeking care could have detrimental impact on outcomes.
Description: Free wall rupture, acute ischemic mitral regurgitation, ventricular septal rupture
Measure: The primary endpoint is a composite of death from all causes and mechanical complications of acute myocardial infarction (MI) Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Description: Compare the number of patients presenting to cardiology department with acute myocardial infarction in 2019 versus in 2020
Measure: Rates of patients presenting with acute myocardial infarction Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Description: Correlation between clinical patient profile and the degree of affection of regions by COVID-19
Measure: Patient profile during admission for acute myocardial infarction Time: 3 months (between March 1 to May 31Description: Correlation between the delay between onset of symptoms - first medical contact - coronary angiography room and the degree of affection of regions by COVID-19
Measure: Medical care times analysis Time: 3 months (between March 1 to May 31)Description: Delay in minutes from symptom onset and STEMI (ST Segment Elevation Myocardial Infarction) diagnosis; and delay in minutes from onset of symptoms and primary PCI (percutaneous coronary intervention)
Measure: Medical care times analysis Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Description: Correlation between the fate of patient and the degree of affection of regions by COVID-19: Number of days in cardiology department, Left Ventricular Ejection Fraction at discharge, presence of hemodynamic complications, presence of mechanical complications, transfer to intensive care unit, infection with COVID-19 during hospitalization, living status at discharge
Measure: Clinical evolution of patients Time: 3 months (between March 1 to May 31)Description: Number of in hospital outcomes including orotracheal intubation, cardiogenic shock, arrhythmias (ventricular tachycardia of ventricular fibrillation) and in hospital cardiac arrest
Measure: Clinical evolution of patients Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Description: Number of patient admitted in cardiology department with STEMI (ST Segment Elevation Myocardial Infarction)
Measure: STEMI (ST Segment Elevation Myocardial Infarction) admissions incidence rates Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Description: Correlation between the number of patients who underwent systemic thrombolysis and the degree of affection of regions by COVID-19
Measure: Proportion of patients who underwent systemic thrombolysis Time: 3 months (between March 1 to May 31)Description: Number of patient admitted in cardiology department for acute myocardial infarction infected with COVID-19
Measure: Proportion of patients infected with COVID-19 Time: 3 months (between March 1 to May 31)The current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.
Description: Acute myocardial infarction as diagnosed by ST segment elevation or depression or inverted T wave on 12-lead EKG and elevated levels of cardiac troponins above the 99% of the normal values. A. Acute MI (STEMI and NSTEMI). B. Aborted on non-aborted sudden cardiac death not attributed to a known etiology. C. Sustained or non-sustained ventricular tachy-arrhythmia not attributed to a known etiology. D. ICD shocks. 3. Absence of suspected or confirmed infection with the COVID19 virus. 4. Definite physical or psycho-social stressful trigger appearing in relation to the COVID-19 situation (lock down stress, financial stress, anger, depression, fear, sorrow, death of a significant person, eating binges, smoking binges, physical stress [carrying walking for shopping and carrying excess weights] ..etc) as judged by a unanimous agreement of three investigators in the steering committee.
Measure: Acute cardiovascular event triggered by COVID-19 stress Time: 4 monthsDescription: Typical ventricular tachycardia on 12-lead EKG or EKG monitor.
Measure: Ventricular tachycardia Time: 4 monthsDescription: acute neurological symptoms of hemiparesis or dysrthria due to brain ischemia proven by computerized tomography or magnatic resonance
Measure: acute stroke Time: 4 monthsDescription: Finding an episode of ventricular tachycardia on interrogation of ICD tracing
Measure: Implantable cardioverter defibrillator (ICD) shock Time: 4 monthsThe ISACS STEMI COVID-19 has been established in response to the emerging outbreak of COVID-19 to provide a European overview to estimate the real impact of COVID-19 pandemic on treatment and outcome of STEMI by primary angioplasty, and to identify any potential category of patients at risk for delay to treatment or no presentation.
Description: Number of patients undergoing primary angioplasty
Measure: Number of patients undergoing primary angioplasty Time: March April 2019 and 2020Description: Number of patients undergoing primary angioplasty later 12 hours from symptoms onset;
Measure: Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset; Time: March April 2019 and 2020Description: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission
Measure: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission Time: March April 2019 and 2020Description: In-Hospital mortality
Measure: In-hospital mortality Time: March April 2019 and 2020Myocardial injury, as assessed by elevation of cardiac troponins (Tnc), is frequent among patients with COVID-19. Although rare autopsy cases reported COVID-19 related myocardial inflammation, the origin of Tnc elevation is unknown to date. Several cardiac causes, such as myocarditis, non-ischemic myocardial injury (NIMI), or myocardial infarction (MI) may lead to Tnc kinetic. Our work will test the hypothesis that during SARS-Cov2 infection, the elevation of cardiac biomarkers could be linked to the occurrence of myocarditis.
Description: Myocardtitis diagnosis in patients COVID+ and troponin+
Measure: characterize the myocardial damage associated with CoV-2 SARS infection Time: Through study completion, an average of 1 yearThe COVID-19 pandemic highlights the importance of the prognosis of co-morbidities, such as coronary artery disease, which significantly increase the risk of mortality in patients infected with SARS-CoV2. Investigators have recently studied the complex links between respiratory infections, particularly pneumonia, and type 2 myocardial infarction (MI) in many respects. The etiology of type 2 MI is based on an imbalance of myocardial oxygen supply/need in the absence of rupture/erosion of atheromatous plaques. Based on the RICO survey data, the investigators investigated whether COVID-19-related sepsis and/or respiratory failure could be an underlying mechanism of MI2.
Novel coronavirus 2019 (COVID-19) has emerged as a major international public health concern. While much of the morbidity and mortality associated with COVID-19 has been attributed to acute respiratory distress syndrome (ARDS) or end-organ failure, emerging data suggest that disorders of coagulation, in particular hypercoagulability and venous thromboembolism (VTE), may represent an additional major, and possibly preventable, complication (Wu C, et al. JAMA Intern Med. 2020 Mar 13. [Epub ahead of print] and Tang N, et al. Thromb. Haemost. 2020 Feb 19. [EPub Ahead of Print]). Abnormal coagulation testing results, especially markedly elevated D-dimer and FDP, have been associated with a poor prognosis in COVID-19 infection. We propose the following Electronic Health Record (EHR)-guided 10000-patient, retrospective observational cohort study to assess VTE incidence, risk factors, prevention and management patterns, and thrombotic outcomes in patients with COVID-19 infection. In order to gain the valuable perspective of other regional and national centers providing care for large populations of COVID-19, we have started a collaborative network with 5 additional sites which will provide us with de-identified data from 1000 patients each. These 5000 patients in addition to the 5000-patient cohort we are enrolling within the Mass General Brigham Network will comprise this study population.
Description: Frequency (%) of arterial or venous thromboembolism
Measure: Frequency of arterial or venous thromboembolism over 30 days Time: 30 daysDescription: Frequency (%) of arterial or venous thromboembolism
Measure: Frequency of arterial or venous thromboembolism over 90 days Time: 90 daysDescription: Frequency (%) of all-cause death, bleeding, and thromboembolic outcomes
Measure: Frequency of all-cause death, bleeding, and thromboembolic outcomes at 30 days Time: 30 daysDescription: Frequency (%) of all-cause death, bleeding, and thromboembolic outcomes
Measure: Frequency of all-cause death, bleeding, and thromboembolic outcomes at 90 days Time: 90 daysThe COVID-19 pandemic has had dramatic effects on health systems and on non-COVID health care. Using French inpatient claims data and retrospectively collected clinical data, the investigators will assess the changes in hospital admissions for acute cardiovascular and neurovascular conditions in France during and after the national lockdown.
Description: Daily number of admissions for acute cardio- and neurivascular conditions in France.
Measure: Daily number of admissions for acute cardio- and neurivascular conditions in France. Time: 1 dayDescription: Specific mortality rate.
Measure: Specific mortality rate. Time: 1 dayThe AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use with the aim of confirming safety and performance throughout their expected lifetime, ensuring the continued acceptability of identified risks, detecting emerging risks on the basis of factual evidence, ensuring the continued acceptability of the benefit-risk ratio, and identifying possible systematic misuse or off-label usage such that the intended use can be verified as appropriate.
Description: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, and TLR Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, and TLR Time: 30 daysDescription: Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive XIENCE BTK and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, and TLR Time: 12 monthsDescription: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion Time: 30 daysDescription: Composite of all-cause death, amputation, TLR, target lesion occlusion will be assessed among the patients who receive Absolute Pro LongLength (LL), Supera 7.5 Outer Diameter (OD), Xpert Pro and its competitors.
Measure: Number of participants with composite of all-cause death, amputation, TLR, target lesion occlusion Time: 12 monthsDescription: Composite of potential complications including implant success, occlusion success, migration will be assessed among the patients who receive AVP or AVP II or AVP 4 and its competitors.
Measure: Number of participants with composite of potential complications (Implant success, occlusion success,migration) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of occlusion success and migration will be assessed among the patients who receive AVP or AVP II or AVP 4 and its competitors.
Measure: Number of participants with composite of occlusion success and migration Time: 30 daysDescription: Composite of vessel dissection, perforation, and thromboembolism during procedure will be assessed among the patients who receive PressureWire X and its competitors.
Measure: Number of participants with composite of vessel dissection, perforation, and thromboembolism Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Signal drift (Signal drift between measurements (Pd/Pa** pressure drift >0.03; <0.97 or >1.03) will be assessed among the patients who receive PressureWire X and its competitors.
Measure: Number of participants with signal drift (Signal drift between measurements (Pd/Pa** pressure drift >0.03; <0.97 or >1.03) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Loss of capture (average time of loss of capture across patients) will be assessed among the patients who receive Pacel FDPC and its competitors.
Measure: Loss of capture Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of potential complications (venous thrombosis, pulmonary emboli, arrhythmias, perforation) will be assessed among the patientswho receive Pacel BPC and its competitors.
Measure: Number of participants with composite of potential complications (venous thrombosis, pulmonary emboli, arrhythmias, perforation) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.
Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) Time: During procedure (from the time a guide wire enters the vasculature till the patient leaves cath lab/procedure room)Description: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.
Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) Time: 30 daysDescription: Composite of all-cause death, MI or target lesion revascularization(TLR) will be assessed among the patients who receive MULTI-LINK 8or MULTI-LINK 8 LL or MULTI-LINK 8 SV and its competitors.
Measure: Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) Time: 12 monthsTo compare myocardial injury in COVID 19 patients presented with myocardial infarction and non COVID Patients presented with myocardial infarction evaluated with CMR
Description: Distribution and Extent of myocardial injury in COVID 19 patients presented with myocardial infarction and non COVID Patients presented with myocardial infarction evaluated with CMR.
Measure: comparison between COVID-19 and COVID-19 presented with myocardial infarction Time: baselineMyocardial infarction (MI) is one of the leading cause s of health loss globally, representing a large proportion of general disability. Anxiety and depression occur in 20-30 percent of patients following MI and have been identified as risk factors for recurrent adverse cardiac event. The purpose of our this study is to develop and evaluate a disease specific cognitive behavioral therapy (C BT) protocol to reduce cardia anxiety, depression, increase physical inactivity and quality of life (Q oL) in patients following MI.
Description: Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.
Measure: Cardiac anxiety questionnaire Time: baselineDescription: Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.
Measure: Cardiac anxiety questionnaire Time: 2 months from baselineDescription: Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.
Measure: Cardiac anxiety questionnaire Time: 8 months from baselineDescription: General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.
Measure: 12-Item Short-Form Health Survey (SF-12) Time: BaselineDescription: General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.
Measure: 12-Item Short-Form Health Survey (SF-12) Time: 2 months from baselineDescription: General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.
Measure: 12-Item Short-Form Health Survey (SF-12) Time: 8 months from baselineDescription: Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.
Measure: Body Sensation Questionnaire Time: BaselineDescription: Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.
Measure: Body Sensation Questionnaire Time: 2 months from baselineDescription: Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.
Measure: Body Sensation Questionnaire Time: 8 months from baselineDescription: Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression.
Measure: Patient Health Questionnaire-9 Time: BaselineDescription: Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression.
Measure: Patient Health Questionnaire-9 Time: 2 months from BaselineDescription: Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression.
Measure: Patient Health Questionnaire-9 Time: 8 months from BaselineDescription: General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.
Measure: Generalized Anxiety Disorder 7-item Time: BaselineDescription: General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.
Measure: Generalized Anxiety Disorder 7-item Time: 2 months from baselineDescription: General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.
Measure: Generalized Anxiety Disorder 7-item Time: 8 months from baselineDescription: Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.
Measure: The Godin Leisure-time Exercise Time: BaselineDescription: Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.
Measure: The Godin Leisure-time Exercise Time: 2 months from BaselineDescription: Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.
Measure: The Godin Leisure-time Exercise Time: 8 months from BaselineDescription: Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.
Measure: Tampas Scale for Kinesophobia-Heart version Time: BaselineDescription: Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.
Measure: Tampas Scale for Kinesophobia-Heart version Time: 2 months from BaselineDescription: Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.
Measure: Tampas Scale for Kinesophobia-Heart version Time: 8 months form BaselineDescription: Treatment satisfaction, score ranging from 0 to 32, with a higher score indication more satisfaction with the treatment.
Measure: Client satisfaction Questionnaire Time: 2 months from BaselineDescription: Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').
Measure: Adverse events Time: 2 months from baselineDescription: Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').
Measure: Adverse events Time: 8 months from baselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports